Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.

Meera Patel,Lawrence G. Lum,Abhinav Deol,Archana Thakur,Elisabeth I. Heath,Wei Chen,Kimberlee Dobson,Joseph A. Fontana,Ulka N. Vaishampayan

Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.

2020

Meera Patel
Lawrence G. Lum
Abhinav Deol
Archana Thakur
Elisabeth I. Heath
Wei Chen
Kimberlee Dobson
Joseph A. Fontana
Ulka N. Vaishampayan

97Background: Immune checkpoint inhibitors (ICI) have demonstrated only modest efficacy in metastatic castrate resistant prostate cancer (mCRPC). Anti-HER2 and Anti-CD3 bispecific antibody armed ac...

Keywords:

Immunotherapy
Cancer research
Pathology
Immune checkpoint
Antibody
Castrate-resistant prostate cancer
Pembrolizumab
Medicine
immune checkpoint inhibitors
bispecific antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations